MedPath

Tagged News

iBio Advances AI-Driven Obesity Pipeline with Myostatin and Activin E Antibody Therapies

Monoclonal AntibodyPrecision Medicine
  • iBio will present promising preclinical data on its long-acting Myostatin antibody IBIO-600 and Activin E targeting therapies for obesity and cardiometabolic diseases.
  • The company will announce a third target in its AstralBio Collaboration during a June 24 conference call, expanding its precision antibody therapy pipeline.
  • iBio's AI-driven approach combines proprietary 3D modeling with computational biology to develop next-generation antibody medicines with potentially better tolerability and sustainable efficacy.
  • The biotech company is positioning itself to address significant unmet medical needs in obesity treatment through targeted, longer-lasting therapeutic approaches.

Denovo Biopharma Out-Licenses Biomarker-Guided Depression Drug DB104 to Taiwan Partner

Precision MedicineAI
  • Denovo Biopharma has granted exclusive rights to develop and commercialize DB104 (liafensine) in Taiwan to Chuang Yi Global Asset Management Co., Ltd.
  • DB104 is a first-in-class triple reuptake inhibitor that targets serotonin, norepinephrine, and dopamine transporters for treatment-resistant depression.
  • The drug utilizes a novel pharmacogenomic biomarker within the ANK3 gene discovered through AI and whole genome scanning to predict efficacy.
  • Taiwan currently has no approved antidepressants for treatment-resistant depression, representing a significant unmet medical need in the region.

Monument Therapeutics Reports Positive Phase I Results for Novel Schizophrenia Cognitive Treatment MT1988

Precision Medicine
  • Monument Therapeutics announced positive Phase I results for MT1988, a novel fixed-dose combination treatment targeting cognitive impairment associated with schizophrenia (CIAS).
  • The study demonstrated favorable safety and tolerability profiles for MT1988, which combines two well-established small molecules acting on nicotinic receptors.
  • These results represent an important milestone in addressing CIAS, a core aspect of schizophrenia that significantly impacts patients' daily functioning yet remains without approved treatment options.
  • The positive Phase I data supports advancement of MT1988 into Phase II clinical development for CIAS and related conditions.

Spanish Researchers Develop DNA Test to Predict Chemotherapy Resistance, Clinical Trials Set for 2026

Precision Medicine
  • Spanish National Cancer Research Centre (CNIO) scientists have developed a genomic test that predicts which patients will not respond to three common chemotherapy types, potentially sparing 20-50% of cancer patients from ineffective treatment and severe side effects.
  • The test analyzes chromosomal instability signatures in tumor DNA to identify resistance patterns for platinum-based, taxane, and anthracycline chemotherapies across multiple cancer types including breast, prostate, ovarian, and sarcoma cancers.
  • Validation studies using data from 840 patients demonstrated the test's effectiveness, with clinical trials planned for 2026 following funding from the Spanish Ministry for Digital Transformation and Public Service.
  • The technology, developed in collaboration with University of Cambridge and startup Tailor Bio, represents a breakthrough in precision medicine by transforming conventional chemotherapies into targeted treatments.

Researchers Advance Nanoscale Drug Delivery Systems with Targeted Cell Recognition and Biological Signal Response

Targeted TherapyPrecision Medicine
  • Researchers have developed nanoscale drug delivery systems capable of delivering therapeutic agents directly to specific cells or tissues while minimizing side effects and enhancing treatment efficacy.
  • These systems can be engineered with surface modifications to recognize and bind to specific receptors on diseased cells, enabling precise molecular-level targeting.
  • The nanosystems demonstrate the ability to respond to specific biological signals, ensuring drugs are released only at the intended treatment site.
  • Various materials including lipids, polymers, and inorganic nanoparticles are being utilized to construct these carriers, with each material influencing stability, biocompatibility, and therapeutic release profiles.

UNC Lineberger Cancer Center Leads $28 Million ARPA-H Trial to Revolutionize Metastatic Breast Cancer Treatment

Precision Medicine
  • The UNC Lineberger Comprehensive Cancer Center received $28 million from ARPA-H to develop EVOLVE, an innovative clinical trial that adapts metastatic breast cancer treatment in real-time based on tumor changes.
  • The trial will enroll up to 700 patients and use biomarkers, including circulating tumor DNA, to detect treatment resistance early and modify therapy before symptoms return.
  • EVOLVE represents a paradigm shift from traditional clinical trials by continuously monitoring tumor evolution and matching patients to the most promising therapies as their cancer changes.
  • The collaborative effort involves 15 institutions across the Translational Breast Cancer Research Consortium, addressing the critical need for curative therapies in metastatic breast cancer where only one in three patients survive beyond five years.

Researchers Develop First Risk Prediction Model for Early-Stage Hodgkin's Lymphoma

Precision MedicineOncology
  • An international research team has developed and validated the first individualized risk prediction model for early-stage classic Hodgkin's lymphoma, called the Early-stage Hodgkin International Prognostication Index (E-HIPI).
  • The model was developed using data from over 3,000 patients in four international phase III clinical trials and validated in more than 2,300 patients from real-world registry cohorts.
  • E-HIPI uses routine clinical measures like patient sex, tumor size, hemoglobin and albumin levels to predict two-year progression-free survival and outperformed existing classification systems.
  • The research team created interactive online risk calculators to support shared decision-making between clinicians and patients, with findings published in NEJM Evidence.

dGenThera and Nusano Partner to Scale Astatine-211 Production for Next-Generation Cancer Therapy

Precision MedicineOncology
  • dGenThera and Nusano signed a letter of intent to provide reliable access to high-purity astatine-211, a best-in-class alpha-emitting isotope for targeted cancer therapy.
  • Nusano's breakthrough accelerator technology will increase global At-211 supply by 100-fold through a facility with alpha beam current 10 times greater than all comparable systems combined.
  • The partnership enables dGenThera to advance its theranostic molecular pairs platform, which uses covalently-bonded At-211 to create precision radiotherapies that can cross the blood-brain barrier.
  • At-211's unique properties include pure alpha emission with no problematic daughter isotopes and a 7.2-hour half-life ideal for systemic delivery and tumor targeting.

CNS Oligonucleotide Licensing Deals Surge 339% to $2.81 Billion in 2024

Precision Medicine
  • Licensing agreements for CNS-targeted oligonucleotide therapeutics increased 339% from 2023 to 2024, reaching $2.81 billion in total deal value according to GlobalData's analysis.
  • Antisense oligonucleotides (ASOs) dominated the market with $3.54 billion in cumulative deals from 2021-2025, while siRNAs accounted for $2.51 billion during the same period.
  • Major pharmaceutical companies including AbbVie, Lilly, Roche and Takeda represented 63% of licensing deals, with Ionis Pharmaceuticals leading the field through $13.4 billion in out-licensed assets over the past decade.
  • Arrowhead Pharmaceuticals secured 2025's largest deal worth up to $2.18 billion through an exclusive licensing agreement with Sarepta Therapeutics for rare genetic and CNS disease programs.

MD Anderson Study Identifies Three B-Cell Lymphoma Subgroups with Distinct CD19 CAR-T Response Patterns

CAR-TPrecision Medicine
  • Researchers at MD Anderson Cancer Center analyzed 232 patients with large B-cell lymphoma to identify three distinct tumor microenvironment subgroups with different responses to CD19 CAR-T therapy.
  • The study profiled over 1.8 million cells and validated findings using ZUMA-7 Phase III trial data, revealing that the lymph node subgroup benefits most from CAR-T therapy while the T cell exhausted group shows no significant benefit.
  • The findings provide a precision medicine framework to guide treatment selection and identify patients who may need alternative therapeutic approaches beyond CAR-T cell therapy.
  • The research opens opportunities for targeted therapies in development to address the needs of patients in subgroups with poorer CAR-T outcomes.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy